Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Small Cell Lung Carcinoma"
Show Display Options
Rank Status Study
1 Recruiting Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-Small Cell Lung Cancer
Conditions: Carcinoma of Unknown Primary Origin;   Extensive Stage Small Cell Lung Carcinoma;   Large Cell Lung Carcinoma;   Neuroendocrine Carcinoma;   Newly Diagnosed Carcinoma of Unknown Primary Origin;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Veliparib;   Other: Placebo;   Drug: Etoposide;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
2 Recruiting Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation;   Radiation: selective external radiation therapy
3 Recruiting Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: cisplatin;   Drug: etoposide

Indicates status has not been verified in more than two years